Literature DB >> 2347046

The role of chemotherapy including ifosfamide for ovarian carcinoma. Austrian Collab. Ovarian Cancer Study Group.

K Karrer1, H Salzer, P Sevelda, C Dittrich.   

Abstract

On the basis of the results of earlier studies, 30 departments of gynecology have been cooperating nationwide in Austria since 1980 to promote the use of adjuvant chemotherapy after surgery for cure of ovarian carcinoma in early stages and the role of lymph node dissection and of second-look operation. Results recorded in more than 160 patients treated with adjuvant chemotherapy after so-called radical surgery performed in disease stages I and II demonstrate that only highly differentiated tumours in stage Ia can be cured by surgery only with no further adjuvant treatment. This underlines the necessity for staging. More than 200 patients with TNM stages III and IV were randomized after debulking surgery to receive treatment with different kinds of drug combinations to compare the therapeutic efficacy of a sequential alternating drug regimen consisting of Adriamycin-cisplatin + vincristine-cyclophosphamide + high-dose methotrexate with that of the combination of Adriamycin-cyclophosphamide and that of Adriamycin-cisplatin. High-dosed ifosfamide was also used in pilot studies.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2347046     DOI: 10.1007/bf00685413

Source DB:  PubMed          Journal:  Cancer Chemother Pharmacol        ISSN: 0344-5704            Impact factor:   3.333


  16 in total

1.  Long-term survival of advanced refractory ovarian carcinoma patients with small-volume disease treated with intraperitoneal chemotherapy.

Authors:  S B Howell; S Zimm; M Markman; I S Abramson; S Cleary; W E Lucas; R J Weiss
Journal:  J Clin Oncol       Date:  1987-10       Impact factor: 44.544

2.  The value of second-look operation in patients with advanced epithelial ovarian carcinoma.

Authors:  P Sevelda; C Dittrich; H Salzer
Journal:  Arch Gynecol Obstet       Date:  1989       Impact factor: 2.344

Review 3.  Chemotherapy of ovarian cancer.

Authors:  R F Ozols; R C Young
Journal:  Semin Oncol       Date:  1984-09       Impact factor: 4.929

4.  Cyclophosphamide versus ifosfamide: final report of a randomized phase II trial in adult soft tissue sarcomas.

Authors:  V H Bramwell; H T Mouridsen; A Santoro; G Blackledge; R Somers; J Verwey; P Dombernowsky; M Onsrud; D Thomas; R Sylvester
Journal:  Eur J Cancer Clin Oncol       Date:  1987-03

5.  [Results of the first Austrian multicenter ovarian cancer study: prospective randomized comparison of sequential chemotherapy (adriamycin/cisplatin--vincristine/cyclophosphamide--methotrexate) with 2 standard protocols (adriamycin/cyclophosphamide or adriamycin/cisplatin) in stage III and IV patients].

Authors:  H Salzer; E Gitsch; C Dittrich; P Sevelda; K Karrer; M Schemper; G Stempel-Smekal; M Langer; G Wagner; H Rainer
Journal:  Geburtshilfe Frauenheilkd       Date:  1985-11       Impact factor: 2.915

Review 6.  Comparative activity of ifosfamide and cyclophosphamide.

Authors:  W Brade; S Seeber; K Herdrich
Journal:  Cancer Chemother Pharmacol       Date:  1986       Impact factor: 3.333

7.  Randomized trial of cyclophosphamide plus cisplatin with or without doxorubicin in ovarian carcinoma: a Gynecologic Oncology Group Study.

Authors:  G A Omura; B N Bundy; J S Berek; S Curry; G Delgado; R Mortel
Journal:  J Clin Oncol       Date:  1989-04       Impact factor: 44.544

Review 8.  Ifosfamide.

Authors:  M Zalupski; L H Baker
Journal:  J Natl Cancer Inst       Date:  1988-06-15       Impact factor: 13.506

Review 9.  Ovarian carcinoma: the role of chemotherapy.

Authors:  J T Thigpen; R B Vance; B W Lambuth
Journal:  Semin Oncol       Date:  1988-06       Impact factor: 4.929

10.  High-dose chemotherapy with autologous bone marrow transplantation in patients with refractory ovarian cancer.

Authors:  P O Mulder; P H Willemse; J G Aalders; E G de Vries; D T Sleijfer; C T Sibinga; N H Mulder
Journal:  Eur J Cancer Clin Oncol       Date:  1989-04
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.